Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Genetics of Mucopolysaccharidosis Type II

  • Author: Germaine L Defendi, MD, MS, FAAP; Chief Editor: Maria Descartes, MD  more...
 
Updated: Jul 28, 2015
 

Background

Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a member of a group of inherited metabolic disorders collectively termed the mucopolysaccharidoses (MPSs). The MPSs are caused by a deficiency of lysosomal enzymes required for the degradation of mucopolysaccharides or glycosaminoglycans (GAGs). Eleven distinct single lysosomal enzyme deficiencies are known to cause 7 different and recognized phenotypes of MPS. All of the MPSs are inherited in an autosomal recessive fashion, except for Hunter syndrome, which is inherited as X-linked recessive.

In the early 1900s, Gertrud Hurler and Charles Hunter first described patients with MPSs, whose metabolic disorders now bear their names (MPS I [Hurler syndrome], MPS II [Hunter syndrome]); subsequent MPSs have been assigned numbers and eponyms loosely associated with the chronology and origin of their report. MPS II was first described by Charles Hunter in 1917. This X-linked recessive disorder results from the lysosomal enzyme deficiency of iduronate 2-sulfatase (also labeled as I2S deficiency or iduronate sulfatase deficiency [ISD]). Iduronate sulfatase deficiency leads to the subsequent GAG accumulation of heparan sulfate and chondroitin sulfate B (dermatan sulfate) in the body.

In 1917 at The Royal Society of Medicine Meeting in London, Charles Hunter, a Canadian Professor of Medicine, presented the medical histories of 2 brothers who were later diagnosed with Hunter syndrome. Sixteen years later, physicians Binswanger and Ullrich coined the term dysostosis multiplex to describe the constellation of skeletal findings specific to persons with MPS and other lysosomal storage disorders.

The following are skeletal abnormalities described in dysostosis multiplex:

  • A large skull with a J-shaped sella
  • Anterior hypoplasia of the thoracic and lumbar vertebral bodies
  • Hypoplasia of the pelvis with small femoral heads and coxa valga (a hip deformity in which the angle formed between the head and neck of the femur and its shaft is increased, usually above 135°)
  • Oar-shaped ribs (narrow at the vertebrae and widening anteriorly)
  • Diaphyseal and metaphyseal expansion of long bones with cortical thinning
  • Tapering of the proximal phalanges

In 1952, Brante isolated the stored mucopolysaccharides from hepatic and meningeal tissues in patients with MPS; hence, the term mucopolysaccharidoses was used to describe this family of diseases. In 1957, Dorfman and Lorincz developed clinical assays to detect urinary mucopolysaccharides. Neufeld et al, in the late 1960s, demonstrated that mucopolysaccharide accumulation in fibroblasts from patients with Hurler (MPS I) and Hunter (MPS II) syndromes could be corrected by co-culturing them with fibroblasts or tissue extracts from patients with a differently diagnosed MPSs. This led to the purification and subsequent identification of each defective lysosomal enzyme within the mucopolysaccharidoses syndromes.[1]

All MPSs share the following clinical hallmarks:

  • A chronic progressive clinical course with multisystem involvement
  • Several phenotypic features, such as coarse facial appearance, growth failure, and organomegaly
  • Laboratory findings such as excretion of urinary GAG fragments and leukocyte inclusion bodies
  • Radiographic abnormalities, eg, dysostosis multiplex

Patients with Hunter syndrome are distinguished from patients with other MPSs because of the male dominant pattern due to the X-linked recessive genetic transmission. Females in whom preferential inactivation of the non-altered paternal allele occurs can have features of Hunter syndrome. Also, corneal clouding is not observed in Hunter syndrome and is therefore a key absent distinguishing feature within the MPS syndromes.

Next

Pathophysiology

Glycosaminoglycans (GAGs) are oligosaccharide components of proteoglycans (macromolecules that provide structural integrity and function to connective tissues). The underlying defect in the MPSs is the inability to degrade GAGs. The chronic progressive course is caused by the accumulation of partially degraded GAGs, with resulting thickening of tissue and compromising of cell and organ function over time. Some of the clinical manifestations of GAG accumulation include coarse facial features, corneal clouding, thickened skin, and organomegaly. Manifestations of abnormal cell function include syndromic intellectual disability, growth failure, and skeletal dysplasia.

GAGs accumulate in lysosomes and extracellular tissue and are excreted in the urine. The exact mechanism by which GAG accumulation leads to disease features is unknown but may involve interference in cellular trafficking of molecules, alteration of the extracellular matrix, and interference with cell signaling and cell receptor functions.[2]

The primary GAGs in tissues include dermatan sulfate, heparan sulfate, keratan sulfate, and chondroitin sulfate. They are composed of sulfated sugar and uronic acid residues (except keratin sulfate, which is composed of galactose-6-sulfate alternating with sulfated N-acetylglucosamine residues). GAGs are degraded in a stepwise fashion from the nonreducing end by a series of lysosomal enzymes. Depending on the specific enzyme deficiency, the catabolism of one or more GAGs may be blocked. Clinical features in patients vary depending on the tissue distribution of the affected substrate and the degree of enzyme deficiency.

Dermatan sulfate is found mostly in skin but is also found in blood vessels, heart valves, lungs, and tendons; thus, accumulation of this GAG results in a characteristic skin deposition, myxomatous valvular changes (mitral valve prolapse), and progressive restrictive lung disease. Heparan sulfate is an essential component of nerve cell membranes; therefore, accumulation causes progressive neurological deterioration. Keratan sulfate accumulation leads to skeletal deformities. Dermatan and heparan sulfate accumulate in patients with MPS II owing to the lack of lysosomal enzyme, iduronate sulfatase (IDS).[3]

Hunter syndrome is distinct from the other mucopolysaccharidoses in that it is genetically inherited as an X-linked recessive disorder. The genetic locus has been mapped to Xq28. The gene defective in this disorder encodes for IDS.[4, 5] To understand the pathogenesis of genetic disorders, animal models can give important clues. For Hunter syndrome, a MPS II mouse model has been engineered to further understand the disease process.[6, 7]

Previous
Next

Epidemiology

Frequency

United States

Incidence is unknown at present, but estimates may soon be available, following the institution of metabolic newborn screening for lysosomal storage disorders. Development of newborn screening strategies is underway.[8]

International

The estimated incidence of MPS II widely varies. The estimated incidence is 1 case per 34,000 in Israel, 1 case per 111,000 in British Columbia, and 1 case per 132,000 in the United Kingdom.[9, 10, 11] Recent studies from Germany and the Netherlands report an overall incidence of 1 case in 140,000-330,000 live births, and, more specifically, 1 case per 77,000 male births.[12]

Mortality/Morbidity

Two types of Hunter syndrome are recognized; a severe form, designated as type A (MPS IIA), and a milder form, designated as type B (MPS IIB). These forms represent the two ends of a clinical spectrum of severity. The distinction is clinically based because iduronate sulfatase (IDS) activity is equally depressed in the laboratory assay used to diagnose both types of Hunter syndrome.

MPS IIA, the severe type, has clinical features similar to those observed with Hurler syndrome, except that corneal clouding is not seen and multisystem involvement does not progress as quickly as seen in Hurler syndrome. In MPS IIA, clinical manifestations become evident in the first few years of life. Children are developmentally delayed and are often hearing impaired with progression to deafness.

Complications in older patients with MPS IIA include carpal tunnel syndrome with entrapment of the medial nerve and degenerative disease of the hips. Subsequent slow systematic somatic and neurologic progression ultimately leads to death in adolescence; however, some patients may live into their second and third decades of life. The cause of death is frequently cardiopulmonary failure secondary to upper airway obstruction and cardiovascular involvement. Incidence of sudden death is about 11%.[13]

Children with MPS IIB (mild type) resemble children with Hurler/Scheie (MPS IH/S) or Scheie syndromes (MPS IS). These children usually have normal intelligence. They may develop airway obstruction secondary to accumulation of mucopolysaccharide in the trachea and bronchi. Patients survive well into adulthood and may live into their seventh decade of life. Most patients will develop valvular heart disease.

Race

Hunter syndrome is panethnic and rare; however, a higher incidence has been noted in the Jewish population living in Israel.

Sex

Inheritance is X-linked recessive, and affected males do not usually reproduce. The disorder is occasionally diagnosed in females consequent to skewed X-inactivation, with the active X carrying the mutation in the iduronate sulfatase (IDS) allele.[14]

Age

MPS IIA is typically diagnosed in children aged 2-4 years. MPS IIB may not be diagnosed until adolescence or adulthood.

Previous
 
 
Contributor Information and Disclosures
Author

Germaine L Defendi, MD, MS, FAAP Associate Clinical Professor, Department of Pediatrics, Olive View-UCLA Medical Center

Germaine L Defendi, MD, MS, FAAP is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Margaret M McGovern, MD, PhD Professor and Chair of Pediatrics, Stony Brook University School of Medicine

Margaret M McGovern, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Society of Human Genetics

Disclosure: Nothing to disclose.

Chief Editor

Maria Descartes, MD Professor, Department of Human Genetics and Department of Pediatrics, University of Alabama at Birmingham School of Medicine

Maria Descartes, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics, American Medical Association, American Society of Human Genetics, Society for Inherited Metabolic Disorders, International Skeletal Dysplasia Society, Southeastern Regional Genetics Group

Disclosure: Nothing to disclose.

Additional Contributors

Karl S Roth, MD Retired Professor and Chair, Department of Pediatrics, Creighton University School of Medicine

Karl S Roth, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American College of Nutrition, American Pediatric Society, American Society for Nutrition, American Society of Nephrology, Association of American Medical Colleges, Medical Society of Virginia, New York Academy of Sciences, Sigma Xi, Society for Pediatric Research, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Nancy E Braverman, MS, MD Associate Professor, Department of Human Genetics, McGill University

Nancy E Braverman, MS, MD is a member of the following medical societies: Alpha Omega Alpha, Society for Inherited Metabolic Disorders, Society for the Study of Inborn Errors of Metabolism, American Society of Human Genetics

Disclosure: Nothing to disclose.

Acknowledgements

Mary Kay Conover-Walker, MSN, PNP Pediatric Nurse Practioner, Institute of Genetic Medicine, Johns Hopkins Hospital

Mary Kay Conover-Walker, MSN, PNP is a member of the following medical societies: American Academy of Allergy Asthma and Immunology and Association of Clinical Research Professionals

Disclosure: Nothing to disclose.

Cydney L Fenton, MD Director, Center for Diabetes and Endocrinology, Akron Children's Hospital

Cydney L Fenton, MD is a member of the following medical societies: American Academy of Pediatrics, American Diabetes Association, Pediatric Endocrine Society, and The Endocrine Society

Disclosure: Nothing to disclose.

Vinayak Kottoor, MD Resident, Department of Genetics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University Hospital

Disclosure: Nothing to disclose.

William Rogers, MD Chief, Pediatric Endocrinology and Pediatric Clinic, Wilford Hall Medical Center

Disclosure: Nothing to disclose.

References
  1. Giugliani R. Mucopolysacccharidoses: From understanding to treatment, a century of discoveries. Genet Mol Biol. 2012 Dec. 35 (4 (suppl)):924-31. [Medline].

  2. Clarke LA. Idursulfase for the treatment of mucopolysaccharidosis II. Expert Opin Pharmacother. 2008 Feb. 9(2):311-7. [Medline].

  3. Brusius-Facchin AC, Abrahão L, Schwartz IV, Lourenço CM, Santos ES, Zanetti A, et al. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence. Gene. 2013 Sep 10. 526(2):150-4. [Medline].

  4. Timms KM, Lu F, Shen Y, et al. 130 kb of DNA sequence reveals two new genes and a regional duplication distal to the human iduronate-2-sulfate sulfatase locus. Genome Res. 1995 Aug. 5(1):71-8. [Medline].

  5. Timms KM, Bondeson ML, Ansari-Lari MA, et al. Molecular and phenotypic variation in patients with severe Hunter syndrome. Hum Mol Genet. 1997 Mar. 6(3):479-86. [Medline].

  6. Garcia AR, Pan J, Lamsa JC, Muenzer J. The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J Inherit Metab Dis. 2007 Sep 16. [Medline].

  7. Friso A, Tomanin R, Alba S, Gasparotto N, Puicher EP, Fusco M, et al. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J Gene Med. 2005 Nov. 7 (11):1482-91. [Medline].

  8. Matern D. Newborn screening for lysosomal storage disorders. Acta Paediatr Suppl. 2008 Apr. 97(457):33-7. [Medline].

  9. Lowry RB, Applegarth DA, Toone JR, MacDonald E, Thunem NY. An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum Genet. 1990 Aug. 85(3):389-90. [Medline].

  10. Schaap T, Bach G. Incidence of mucopolysaccharidoses in Israel: is Hunter disease a "Jewish disease"?. Hum Genet. 1980. 56(2):221-3. [Medline].

  11. Young ID, Harper PS. Incidence of Hunter's syndrome. Hum Genet. 1982. 60(4):391-2. [Medline].

  12. Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J. Initial report from the Hunter Outcome Survey. Genet Med. 2008 Jul. 10(7):508-16. [Medline].

  13. Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol. 1983 Aug. 25(4):481-9. [Medline].

  14. Clarke JT, Wilson PJ, Morris CP, et al. Characterization of a deletion at Xq27-q28 associated with unbalanced inactivation of the nonmutant X chromosome. Am J Hum Genet. 1992 Aug. 51(2):316-22. [Medline].

  15. Young ID, Harper PS, Newcombe RG, Archer IM. A clinical and genetic study of Hunter's syndrome. 2. Differences between the mild and severe forms. J Med Genet. 1982 Dec. 19(6):408-11. [Medline].

  16. Young ID, Harper PS. Mild form of Hunter's syndrome: clinical delineation based on 31 cases. Arch Dis Child. 1982 Nov. 57(11):828-36. [Medline].

  17. Spranger J, Cantz M, Gehler J, Liebaers I, Theiss W. Mucopolysaccharidosis II (Hunter disease) with corneal opacities. Report on two patients at the extremes of a wide clinical spectrum. Eur J Pediatr. 1978 Aug 17. 129(1):11-6. [Medline].

  18. Caruso RC, Kaiser-Kupfer MI, Muenzer J, Ludwig IH, Zasloff MA, Mercer PA. Electroretinographic findings in the mucopolysaccharidoses. Ophthalmology. 1986 Dec. 93(12):1612-6. [Medline].

  19. Beck M. Papilloedema in association with Hunter's syndrome. Br J Ophthalmol. 1983 Mar. 67(3):174-7. [Medline].

  20. Beck M, Cole G. Disc oedema in association with Hunter's syndrome: ocular histopathological findings. Br J Ophthalmol. 1984 Aug. 68(8):590-4. [Medline].

  21. Hobolth N, Pedersen C. Six cases of a mild form of Hunter syndrome in five generations. Three affected males with progeny. Clin Genet. 1978. 20:121.

  22. Rozdzynska A, Tylki-Szymanska A, Jurecka A, Cieslik J. Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II. Acta Paediatr. 2011 Mar. 100(3):456-60. [Medline].

  23. Schulze-Frenking G, Jones SA, Roberts J, Beck M, Wraith JE. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis. 2011 Feb. 34(1):203-8. [Medline]. [Full Text].

  24. Isogai K, Sukegawa K, Tomatsu S, et al. Mutation analysis in the iduronate-2-sulphatase gene in 43 Japanese patients with mucopolysaccharidosis type II (Hunter disease). J Inherit Metab Dis. 1998 Feb. 21(1):60-70. [Medline].

  25. Crotty PL, Braun SE, Anderson RA, Whitley CB. Mutation R468W of the iduronate-2-sulfatase gene in mild Hunter syndrome (mucopolysaccharidosis type II) confirmed by in vitro mutagenesis and expression. Hum Mol Genet. 1992 Dec. 1(9):755-7. [Medline].

  26. Birot AM, Delobel B, Gronnier P, Bonnet V, Maire I, Bozon D. A 5-megabase familial deletion removes the IDS and FMR-1 genes in a male Hunter patient. Hum Mutat. 1996. 7(3):266-8. [Medline].

  27. Hopwood JJ, Bunge S, Morris CP, et al. Molecular basis of mucopolysaccharidosis type II: mutations in the iduronate-2-sulphatase gene. Hum Mutat. 1993. 2(6):435-42. [Medline].

  28. Rathmann M, Bunge S, Beck M, Kresse H, Tylki-Szymanska A, Gal A. Mucopolysaccharidosis type II (Hunter syndrome): mutation "hot spots" in the iduronate-2-sulfatase gene. Am J Hum Genet. 1996 Dec. 59(6):1202-9. [Medline].

  29. Clarke JT, Willard HF, Teshima I, Chang PL, Skomorowski MA. Hunter disease (mucopolysaccharidosis type II) in a karyotypically normal girl. Clin Genet. 1990 May. 37(5):355-62. [Medline].

  30. Kamin W. Diagnosis and management of respiratory involvement in Hunter syndrome. Acta Paediatr Suppl. 2008 Apr. 97(457):57-60. [Medline].

  31. Chmielarz I, Gabig-Ciminska M, Malinowska M, Banecka-Majkutewicz Z, Wegrzyn A, Jakobkiewicz-Banecka J. Comparison of siRNA-mediated silencing of glycosaminoglycan synthesis genes and enzyme replacement therapy for mucopolysaccharidosis in cell culture studies. Acta Biochim Pol. 2012. 59(4):697-702. [Medline].

  32. Jurecka A, Krumina Z, Zuber Z, Rózdzynska-Swiatkowska A, Kloska A, Czartoryska B, et al. Mucopolysaccharidosis type II in females and response to enzyme replacement therapy. Am J Med Genet A. 2012 Feb. 158A(2):450-4. [Medline].

  33. Meikle PJ, Grasby DJ, Dean CJ, et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab. 2006 Aug. 88(4):307-14. [Medline].

  34. Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis. 1999 Jun. 22(5):638-48. [Medline].

  35. Mullen CA, Thompson JN, Richard LA, Chan KW. Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia. Bone Marrow Transplant. 2000 May. 25(10):1093-7. [Medline].

  36. Martin R, Beck M, Eng C, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008 Feb. 121(2):e377-86. [Medline].

  37. Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007 Mar. 90(3):329-37. [Medline].

  38. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006 Aug. 8(8):465-73. [Medline].

  39. [Guideline] Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008 Mar. 167(3):267-77. [Medline].

  40. Al Sawaf S, Mayatepek E, Hoffmann B. Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed. J Inherit Metab Dis. 2008 Aug. 31(4):473-80. [Medline].

  41. Kampmann C, Beck M, Morin I, Loehr JP. Prevalence and characterization of cardiac involvement in hunter syndrome. J Pediatr. 2011 Aug. 159(2):327-331.e2. [Medline].

  42. Kwon JY, Ko K, Sohn YB, et al. High prevalence of carpal tunnel syndrome in children with mucopolysaccharidosis type II (Hunter syndrome). Am J Med Genet A. 2011 Jun. 155(6):1329-35. [Medline].

  43. Holt J, Poe MD, Escolar ML. Early Clinical Markers of Central Nervous System Involvement in Mucopolysaccharidosis Type II. J Pediatr. 2011 Aug. 159(2):320-326.e2. [Medline].

  44. Neufeld EF, Muenzer J. The Mucopolysaccharidoses. The Metabolic Bases of Inherited Disease. 8th ed. McGraw-Hill; 2000. 3421-52.

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.